-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Risvodetinib Succinate in Constipation
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Risvodetinib Succinate in Constipation report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Risvodetinib Succinate in Constipation Drug Details: Risvodetinib succinate (Ikt-148009) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Risvodetinib Succinate in Dysphagia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Risvodetinib Succinate in Dysphagia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Risvodetinib Succinate in Dysphagia Drug Details: Risvodetinib succinate (Ikt-148009) is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Risvodetinib Succinate in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Risvodetinib Succinate in Parkinson's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Risvodetinib Succinate in Parkinson's Disease Drug Details: Risvodetinib succinate (Ikt-148009) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Cagrilintide + Semaglutide) in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Cagrilintide + Semaglutide) in Metabolic Dysfunction-Associated Steatohepatitis (MASH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Cagrilintide + Semaglutide) in Metabolic Dysfunction-Associated Steatohepatitis (MASH)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Cagrilintide + Semaglutide) in Type 2 Diabetes
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Cagrilintide + Semaglutide) in Type 2 Diabetes report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Cagrilintide + Semaglutide) in Type 2 Diabetes Drug Details:...
-
Sector Analysis
Uranium Mining Market Analysis by Reserves, Production, Assets, Demand Drivers and Forecast to 2030
Empower your strategies with our Global Uranium Mining to 2026 report and make more profitable business decisions.Uranium Mining Market Report Overview Uranium production was estimated to be 54kt in 2023. Ramping up of the uranium production at Canada’s McArthur River mine, which re-started in November 2022, was the leading factor for the growth in production during 2023. The production growth is further expected to be driven by the planned increase in output from Kazakhstan’s largest uranium producer, Kazatomprom, and the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Risvodetinib in Constipation
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Risvodetinib in Constipation Drug Details: Risvodetinib (Ikt-148009) is under development for the treatment of Parkinson’s disease...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Risvodetinib in Dysphagia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Risvodetinib in Dysphagia Drug Details: Risvodetinib (Ikt-148009) is under development for the treatment of Parkinson’s disease...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Cagrilintide + Semaglutide) in Obesity
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Cagrilintide + Semaglutide) in Obesity report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Cagrilintide + Semaglutide) in Obesity Drug Details: A fixed dose combination...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Imatinib Mesylate in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Imatinib Mesylate in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Drug Details: Imatinib mesylate...